Upadacitinib can be administered alone or in combination with methotrexate or DMARDs.416 Analysis of RA patient plasma proteins suggested that treatment with upadacitinib normalizes key pathways associated with RA pathobiology, including IL-1, IL-6, IFNγ, and TNF. The gene discussed is IL6; the disease is rheumatoid arthritis.